On the afternoon of January 26, Dr. Machida from the Sales Planning and Development Group of MicroBiopharm Japan, and Mr. Wang, Business Development Manager of Main Life, visited Shenzhen Cell Valley for exchange. Chairman Professor Shi Yuanyuan, Director of the General Office Luan Zhishi, Deputy Director of Quality Management Department Li Rongyou, and Deputy Director of Production Department Li Huaxiu warmly received them and held discussions on the future development direction of biomedical industries in China and Japan, as well as strategic cooperation areas between the two parties.

First, Director of the General Office Luan Zhishi led the entrepreneurs to visit the Smart Exhibition Hall, providing a detailed explanation in Japanese of Shenzhen Cell Valley's development history, core technologies, and recent major breakthroughs in R&D and clinical applications. Subsequently, Deputy Director of Production Li Huaxiu and Deputy Director of Quality Management Li Rongyou accompanied the guests to visit the production workshops and R&D laboratories, introducing the management mechanisms that ensure efficient production operations and high-quality product release.

During the symposium, Chairman Shi Yuanyuan extended a warm welcome to the two entrepreneurs and elaborated on Deep Harbour Cell Valley's technological breakthroughs, innovative achievements, and successful clinical cases in cell and gene therapy. As China's only one-stop CRO/CDMO outsourcing service provider equipped with industrial-grade retroviral vector technologies (such as the PackRV-SS system), Deep Harbour Cell Valley has established a presence in Shenzhen, Beijing, and Zhongshan. The company provides clients with a professional, efficient, one-stop full-chain service covering early-stage R&D, vector design, viral production, cell production, and regulatory filing assistance. Adhering to its corporate mission of "Cells Benefit All Lives, Genes Create the Future," Deep Harbour Cell Valley will continue to steadily expand into overseas markets. It aims to fully leverage the advantages of retroviral vectors in the industrialization of cell therapy drugs, offering innovative ideas for advancing basic research and epoch-making solutions for treating cancer and rare diseases.Dr. Machida and Mr. Wang expressed high appreciation for Deep Harbour Cell Valley's strategic layout. They provided a detailed overview of MicroBiopharm Japan's development history, core businesses, client base, production bases, and core competitiveness. Based on a comprehensive understanding of each other's business sectors, core products, clientele, and relevant regulations in China, Japan, and other overseas markets, both parties deeply explored potential synergies for cooperation and reached a consensus on the future direction of biopharmaceutical development. This exchange visit has laid a solid foundation for future collaboration. Both sides look forward to exploring new possibilities in the treatment of diseases such as cancer and in medical research, contributing to the high-quality development of the cell and gene therapy industry.

MicroBiopharm Japan is a fermentation expert with 70 years of experience, supporting partners at all stages of research, development, and commercial production using microorganisms. Committed to operating as a specialized biopharmaceutical CDMO company, it provides high-quality chemical substances through microbial fermentation and transformation, as well as innovative biopharmaceutical molecules for new modalities, thereby contributing to sustainable development.

Since 1971, Main Life has been dedicated to providing high-quality pharmaceuticals in China, Hong Kong, and Macau.

The founder worked under the guidance of Dr. H. Umezawa, an antibiotic researcher at the Microbial Chemistry Research Foundation in Japan during the 1960s, and established Main Life as a supplier of Japanese antibiotics to Hong Kong and China. Since then, Main Life has introduced specialty pharmaceuticals, medical devices, and healthcare products from renowned manufacturers to the region.

Headquartered in Hong Kong, the company has professional staff and provides one-stop services for the Hong Kong and Macao markets, including market research, registration, warehousing, packaging, marketing and sales, government tender management, safety reporting and named-patient import. It also offers comprehensive pharmaceutical solutions for entering the mainland Chinese market.